A New Framework for Applying AI to Mental Health Drug Development

3:00 PM - 4:00 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 209
Are AI-enabled solutions advancing quickly enough to outpace the rapidly evolving mental health crisis? In the past decade, revolutionary breakthroughs in therapeutic areas including oncology and gene therapy have been enabled by precision medicine. Although tailoring treatments to a patient’s unique biology has proved beneficial and life-saving, mental health has failed to innovate in this way. Finally, innovators have harnessed big data and machine learning approaches to develop digital tools, diagnostics, and therapeutics that show potential to reveal and treat sub-populations of patients within and across CNS disease states. In addition to sharing key findings from recent data readouts, leading big pharma and biotech executives will discuss the most promising technologies of today, how viable brain biomarkers are selected, and how stratifying patients is forever changing the mental health landscape.
Editor, First Opinion
Founder and Chief Executive Officer
Alto Neuroscience
Chief Medical Officer
Head of Neurodevelopment & Psychiatry, Novartis Institutes for Biomedical Research (NIBR)
Chief Business Officer
atai Life Sciences